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Abstract   
Background – Grass pollen–related seasonal allergic rhinoconjunctivitis (SARg) is clinically 
heterogeneous in severity, comorbidities and response to treatment. The component-resolved 
diagnostics disclosed also a high heterogeneity at molecular level. Our study aimed at analyzing the 
characteristics of the IgE sensitization to Phleum pratense molecules and investigating the diagnostic 
relevance of such molecules in childhood. 
Methods - We examined 1120 children (age 4–18y) with SARg. Standardized questionnaires on atopy 
were acquired through informatics platform (AllergyCARDTM). Skin prick tests were performed with 
pollen extracts. Serum IgE to airborne allergens and eight Phleum pratense molecules (rPhl p 1, rPhl 
p 2, rPhl p 4, rPhl p 5b, rPhl p 6, rPhl p 7, rPhl p 11, rPhl p 12) were tested by ImmunoCAP FEIA.  
Results - The analysis of IgE responses against eight Phleum pratense molecules showed 87profiles. 
According to the number of molecules recognized by IgE, the more complex profiles were 
characterized by higher serum total IgE, higher grass-specific serum IgE and higher number and 
degree of sensitization to pollens. The most frequent IgE sensitization profile was the 
monomolecular Phl p 1. Sensitization to Phl p 7 was a reliable biomarker of asthma, whereas Phl p 12 
of oral allergy syndrome. Sensitization to Phl p 7 was associated with a higher severity of SAR, and 
complex profiles were associated with longer disease duration.  
Conclusions - In a large pediatric population, the complexity of IgE sensitization profiles against 
Phleum pratense molecules is related to high atopic features although useless for predicting the 
clinical severity. The detection of serum IgE to Phl p 1, Phl p 7 and Phl p 12 can be used as clinical 
biomarkers of SARg and comorbidities. Further studies in different areas are required to test the 
impact of different IgE molecular profiles on AIT response. 
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Introduction 
Grass pollen–related seasonal allergic rhinoconjunctivitis (SARg) affects millions of people worldwide 
with a noteworthy health (1) and economic burden.(2) Severity, comorbidities (e.g. asthma, oral 
allergy syndrome - OAS) and response to pharmacotherapy and to allergen immunotherapy (AIT) can 
vary among patients. (3) The causes of this clinical heterogeneity are unknown and serological 
biomarkers of disease endotypes are currently missing.(4) The analysis of IgE sensitization at 
molecular level (so-called component-resolved diagnostics, CRD) disclosed a high heterogeneity of 
the molecular IgE sensitization profiles to grass pollen.(5) This observation might explain clinical 
diversity (6) and raise the hypothesis that IgE to individual molecules may serve as predictive 
biomarkers of specific clinical phenotypes and of disease evolution.(7) (8)  
In Europe, eight molecules of Phleum pratense, officially listed by the IUIS Allergen Nomenclature 
Sub-Committee, are frequently used in studies of grass pollen allergy.(9) They include grass specific 
molecules, such as rPhl p 1, rPhl p 2, rPhl p 5 and rPhl p 6, and cross-reactive molecules, such as nPhl 
p 4, rPhl p 7, rPhl p 11 and rPhl p 12.(10) Measurement of serum IgE to these molecules may be 
useful in the management of the grass pollen allergic patient.(11) For example, detection of IgE to 
Phl p 1 may be sufficient to confirm grass pollen allergy in SAR (12); detection of IgE to Phl p 12 may 
predict OAS (12, 13), and the simultaneous detection of IgE to Phl p 1, Phl p 5 and Phl p 12 may 
predict a higher risk of adverse reactions during AIT with grass extract.(14) 
We have previously shown that sensitization to Phleum pratense molecules starts with an IgE 
response to Phl p 1 in early childhood and later grows quantitatively and qualitatively by involving 
other grass molecules.(15) We also described that this “molecular spreading” generates several 
different molecular IgE sensitization profiles, which may then influence the prescription of AIT.(16) 
The present study aims at describing the molecular profile of IgE sensitization to Phleum pretense 
and testing the hypothesis that complex profiles or IgE sensitization to single molecules are useful to 
predict specific clinical phenotypes of SARg. To this end, we measured the concentration of serum 
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IgE to the eight Phleum pratense molecules and assessed IgE complex sensitization profiles in a very 
large population of Italian children affected by SARg, whose clinical phenotype, severity and 
comorbidities had been carefully diagnosed.  
Materials and methods 
Study design and population – The study population was enrolled in a large Italian nationwide 
observational cross-sectional survey (“Panallergens in Pediatrics” [PAN-PED]), conducted by the 
Italian Pediatric Allergy Network (I-PAN) (17). Children were recruited between May 2009 and June 
2011 by 16 pediatric outpatient clinics in 14 Italian cities distributed in 3 main geographic areas: 
Northern Italy (Milan, Verona, Genoa, Parma and Bologna), Central Italy (Empoli, Ascoli Piceno, 
Ostia, three centers in Rome), and Southern Italy & Major Islands (Naples, Benevento, Iglesias, 
Palermo and Crotone). Criteria for eligibility were: a) age 4 to 18 years; b) a history of pollen-induced 
allergic rhinitis and/or asthma in one of the last two pollen seasons; c) positive skin-prick tests (SPT) 
for the relevant pollen extracts. Exclusion criteria were: 1) previous immunotherapy for any pollen 
allergen; 2) other severe chronic diseases. Parents or tutors of all participants provided informed 
written consent to clinical investigations. The ethical committee of each participating center 
approved the study design and procedures. In this analysis, we included only children with SPT to 
Phleum pratense ≥3 mm who were examined for sIgE to all eight Phleum pratense molecules. 
Questionnaire – Internationally validated questionnaires were administered to recruited children’s 
parents: the International Study of Allergy and Asthma in Childhood (18, 19), Allergic Rhinitis and its 
Impact on Asthma (ARIA) classification (20), and the Global Initiative for Asthma (GINA)(21). 
Demographic data, history of atopic disease, occurrence of OAS and triggering foods were also 
recorded. SAR was classified as intermittent or persistent, mild or moderate-severe according to the 
“ARIA classification” (20). An informatics platform (“AllergyCARD™”, TPS Production, Rome, Italy) 
was used for data input.  
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Skin-prick tests – SPT were performed with a panel of commercial extracts (ALK-Abelló, Italy), 
including: Phleum pratense (Timothy grass), Cynodon dactylon (Bermuda grass), Chenopodium album 
(white goosefoot), Betula verrucosa (birch), Cupressus arizonica (cypress), Corylus avellana (hazel), 
Platanus orientalis (plane tree), Olea europaea (olive tree), Parietaria judaica (pellitory), Artemisia 
vulgaris (mugwort), Plantago lanceolata (plantago), Salsola spp. (Russian thistle), Fagus spp. (holm) 
and Ambrosia artemisiifolia (ragweed). Histamine 0.1 mg/ml and glycerol solution were the positive 
and negative controls, respectively. Morrow-Brown needles were used to prick the skin. Readings 
were taken at 15 minutes and a wheal ≥3 mm was regarded as positive.  
IgE assays – All the serum samples were tested for total IgE (tIgE) and specific IgE (sIgE) to pollen 
extracts (Cynodon dactylon, Betula verrucosa, Cupressus arizonica, Platanus orientalis, Olea 
europaea, Parietaria judaica, Artemisia vulgaris, Plantago lanceolata and Ambrosia artemisiifolia) 
and to perennial airborne allergens listed above (ImmunoCAP FEIA; Phadia, Uppsala, Sweden). IgE to 
a panel of Phleum pratense molecules (including rPhl p 1, rPhl p 2, rPhl p 5b, rPhl p 6, rPhl p 7, rPhl p 
11, rPhl p 12) (ImmunoCAP FEIA; Phadia, Uppsala, Sweden) were measured in sera of patients 
showing a SPT wheal reaction ≥ 3 mm elicited by the Phleum pratense extract. IgE reactivity to Phl p 
4 was defined by a positive response on an ELISA with rPhl p 4 in the solid phase (Allergopharma, 
Reinbeck, Germany), as previously described (22). Results were expressed in kilounits per liter 
(kUA/L) and classified as positive or negative according to the cut-off level of 0.35. We additionally 
calculated the Phl p 1 “specific activity” (sIgE to tIgE ratio), as previously described.(23) Patients 
were categorized as “monomolecular”, “oligomolecular”, “polymolecular” in case of IgE recognition 
to 1, 2-4, or 5-8 molecules of Phleum pratense, respectively. The IgE sensitization profiles to the 
eight Phleum pratense molecules were defined according to the Allergen-Profile-Codification-System 
(APCS), as previously reported.(22)  
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Statistics - Data were summarized as numbers (n) and frequencies (%) if they were categorical and 
as mean and standard deviation (SD) if quantitative. The average concentration of tIgE and sIgE 
levels were calculated as geometric mean, specifically for sIgE antibodies only the positive serum 
samples were considered (see the above definition). Comparison of the general characteristics 
between participants included and excluded from this study were evaluated by χ2 test (categorical 
data) and by T-test, when conditions were respected, or Mann Whitney U test (quantitative data). 
To assess the normal distribution of quantitative data, the Shapiro–Wilk test was applied. The 
prevalences of IgE sensitization (≥0.35 kUA/L) to the eight Phleum pratense molecules were 
examined and the frequencies of all different sensitization profiles were identified by APCS 
combinatorial analysis. Trend analysis by one-way ANOVA, when appropriate, or non-parametric 
Jonckheere-Terpstra test for ordered alternatives was used to compare quantitative variables 
between independent groups of patients with: 1) an increasing number of Phleum pratense 
molecules recognized by IgE; 2) a different APCS profile of sensitization after ordering them 
according to the increasing number of Phleum pratense molecules recognized by IgE. With the same 
aim, the Mantel–Haenszel linear-by-linear association χ^2 test for trend was used to compare 
categorical characteristics of clinical outcomes and atopic features. P value of multiple comparison 
was adjusted by Bonferroni’s correction. Generalized estimating equation models taking into 
account multiple measures from the same subject, were utilized to compare patients with different 
IgE sensitization to the individual Phleum pratense molecules. More precisely a categorical variable 
indicating the specific-molecule sensitization for each subject (Phleum pratense index) was included 
in each model as independent factor variable and adjusting all models for the number of Phleum 
pratense molecules recognized by IgE. To estimate the effect of the number of Phleum pratense 
molecules recognized by IgE on sIgE to Dermatophagoides pteronyssinus, a multivariable linear 
regression analysis was applied. The regression model was adjusted by significant factors identified 
through univariate analysis. Missing values were not considered for statistical analyses. A p value 
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<0.05 was considered statistically significant. Statistical analysis was performed by using IBM SPSS 
Statistical software, version 21 (IBM Corporation, Armonk, NY, USA). 
 
Results 
Study population – The target population consisted in 1271 pediatric patients, recruited in the 
context of “PAN-PED” project.(24) The present study evaluated 1120 of these 1271 children, i.e. 
those with a SPT positive reaction to Phleum pratense extract (≥3 mm) and a complete dataset for 
sIgE to the eight Phleum pratense molecules [Figure e1]. We found no differences in age, familiar 
atopy, characteristics of SAR and OAS frequency between children included and excluded from the 
study [Table 1]. By contrast, a male gender, Northern Italian residency, higher atopic reactivity and 
absence of asthma were more common among included patients than among those excluded [Table 
1]. Among the 1120 patients included in the study population, we found that the co-sensitization to 
other pollens represents a frequent event (e.g. 69.1% of patients were sensitized to Olive tree, 
40.8% to Cypress and 38.9 to Birch) [Table e1]. 
Molecular profiles of IgE to Phleum pratense – The analysis of IgE responses against eight Phleum 
pratense molecules in the 1120 participants showed a wide spectrum of 87 different sensitization 
profiles [Figure 1a]. After exclusion of the “0” profile, the arbitrary threshold of 50% of the whole 
study population was covered by the eight most frequent profiles, defined by the APCS code as 
“128” (17.4%), “249” (6.3%), “216” (6.1%), “250” (5.2%), “248” (5.1%), ”251” (4.9%), “192” (4.8%) 
and “152” (3.6%) [Figure 1a]. These eight profiles were further examined in depth (see below). 
Overall, 233/1120 (22%) patients presented a “monomolecular” sensitization profile: of these, only 3 
(1%) were sensitized to Phl p 5, while 195 (84%) were sensitized to Phl p 1 [Figure 1b]. Moreover, 
430/1120 (40%) were sensitized to 2-4 molecules (“oligomolecular”) and 410/1120 (38%) were 
sensitized to >4 molecules (“polymolecular”); 8 of the 1120 patients were sensitized to all the eight 
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molecules [Figure 1b]. The prevalence and the geometric mean level of IgE antibodies to any 
positive reaction to each molecule (≥0.35 kUA/L) were related [Figure e2]. 
Characteristics of IgE sensitization - We analyzed the characteristics of atopic sensitization after 
stratification in relation to three different classifications of the IgE sensitization: A) to each of the 
eight individual molecules; B) to each of the eight most common IgE sensitization profiles; C) to the 
number of molecules recognized by IgE: 
 Individual molecules – The 38/1120 (3%) patients sensitized to Phl p 7 had the highest levels of 
serum tIgE and of sIgE to the Phleum pratense extract or to other pollens, and the highest 
number of SPT positive reactions to the panel of the examined pollen extracts [Table 2a].  
 IgE molecular sensitization profiles – The serum level of tIgE strongly increased in parallel with 
the complexity of the IgE sensitization profiles, ranging from 278 kU/L of the profile “128” 
(monomolecular Phl p 1) to 803 kU/L of the profile “251” (seven IgE recognized molecules). A 
similar trend was followed by the levels of sIgE to the Phleum pratense extract (from 3.4 to 176 
kUA/l) and to Phl p 1 (from 4.1 to 84 kUA/l) and by the overall sensitization to pollens extracts, 
expressed as number of positive SPT reactions or as sum of the serum sIgE antibodies [Table 2b]. 
 Number of Phleum pratense molecules recognized by IgE – The serum levels of tIgE, of sIgE to 
Phleum pratense extract, of sIgE to Phl p 1 and the number or overall degree of sensitization to 
pollens extracts were strongly related to the number of Phleum pratense molecules recognized 
by IgE [Figure 2]. By contrast, the level of sIgE to Dermatophagoides pteronyssinus was inversely 
related to the number of Phleum pratense molecules recognized by IgE (p for trend <0.001) 
[Figure e3]. A multivariable linear regression analysis showed that the number of Phleum 
pratense molecules recognized by IgE had a negative effect on sIgE to Dermatophagoides 
pteronyssinus regardless of relevant confounders factors identified through univariate analysis 
(age, gender, tIgE, pollen not related AR and pollen not related asthma) [Table e2]. 
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Clinical outcomes – Sensitizations to Phl p 7 and Phl p 12 were associated with a longer duration of 
SAR, while sensitization to Phl p 1 with a shorter duration [Table 3a]. Moreover, sensitization to Phl 
p 7 was significantly associated to a higher severity of SAR, with symptoms persisting for >4 
months/year and a higher prevalence of asthma. Finally, sensitization to Phl p 12 was associated 
with OAS (32.4%, p <0.001) [Table 3a]. By contrast, a higher complexity of the APCS profile was 
directly associated to a longer duration of SAR only and it was inversely associated to symptoms 
persisting for >4 months/year, but not to all the other clinical parameters [Table 3b]. 
 
Discussion 
We examined IgE sensitization to eight recombinant Phleum pratense allergenic molecules in the 
sera of 1120 children affected by grass pollen allergy and we found: 1) an extreme heterogeneity of 
the IgE molecular sensitization profiles; 2) a strong relationship of the intrinsic complexity of the 
sensitization profiles with both, the intensity and diversification of the IgE response to other pollens, 
but not with those of IgE response to mites or other indoor allergens; 3) an absolute dominance of 
the IgE sensitization to Phl p 1, which contributes to over 85% of the “monomolecularly” sensitized 
patients; 4) a relatively low frequency of IgE sensitization to Phl p 5, which is rarely 
“monomolecular”; 5) a strong association of IgE sensitization to Phl p 7 and asthma; 6) a strong 
association of IgE sensitization to Phl p 12 and OAS; 7) no relevant association between a given IgE 
sensitization profile and the clinical phenotype of SAR. To our knowledge, this is the first 
comprehensive analysis of the clinical relevance of IgE sensitization profiles to eight allergenic 
molecules of Phleum pratense in a large population of grass pollen allergic children.  
Heterogeneity of the IgE sensitization profiles – Our molecular combinatorial analysis confirms that 
the qualitative homogeneity of IgE sensitization to the extract of Phleum pratense among grass 
pollen allergic patients is only apparent. The number of described grass pollen IgE sensitization 
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profiles, originally limited to 39 (22), is now expanded to 87, suggesting that, theoretically, all the 
256 possible combinations could be observed if the study population was big enough. This high 
heterogeneity had been already confirmed among German (3) grass pollen allergic patients. Our 
study adds that some profiles are much more frequent than others, so their clinical relevance can be 
investigated.  
Polymolecular sensitization predicts polysensitization to pollens but not to indoor allergens – Not 
surprisingly, the more complex profiles were characterized by a higher levels of tIgE and sIgE to 
Phleum pratense extract and by a longer history of SAR. This data confirms our previous 
observations in the MAS birth cohort (15, 25) and supports the concept of the atopic march. 
Moreover, a higher diversity of the IgE response to the individual molecules of Phleum pratense was 
strongly and linearly associated to both, a higher number and a higher degree of IgE sensitization to 
other pollens. Figure 2 shows for the first time that the polymolecular IgE sensitization profiles are 
strongly associated with pollen extract polysensitization. A strong propensity to atopic responses 
might underlie the molecular spreading of IgE responses not only to an individual allergen source 
(i.e. Phleum pratense) but also to different allergen sources (i.e. other pollens). However, we did not 
find any correlation between the number of Phleum pratense molecules recognized by IgE and the 
prevalence or intensity of the IgE response to cat and alternaria allergens. Surprisingly, the 
prevalence and the levels of IgE to Dermatophagoides pteronyssinus were even strongly and linearly 
inversely correlated to the number of Phleum pratense molecules recognized by IgE. This intriguing 
observation should be examined with caution, as we cannot exclude a selection bias due to our 
study inclusion criteria. Nevertheless, these data suggest that the molecular spreading process is 
characterized by a certain degree of “selectivity”, whose nature and mechanisms should be better 
clarified in longitudinal studies (26).  
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IgE to Phl p 1, Phl p 7 and Phl p 12 as diagnostic biomarkers – Our results suggest that sIgE to a few 
individual molecules of Phleum pratense can be used as diagnostic biomarkers:  
 Phl p 1 – As already reported by previous studies (5, 27, 28), over 89% of the grass pollen 
sensitized patients had IgE to Phl p 1 and the most frequent profile was APCS “128”, i.e. a 
monomolecular IgE sensitization to Phl p 1. By contrast, monomolecular IgE sensitization to Phl p 
5 (APCS “16”) was observed in only 3 patients, while only 39 children were sensitized to Phl p 5 
but not to Phl p 1. In a Czech population (29), IgE sensitization to Phl p 5 was less frequent in 82 
children than in 48 adults with grass pollen allergy (59.8% vs 79.1%), while over 90% of children 
and adults were sensitized to Phl p 1. This study supported the hypothesis (15) that Phl p 1 is the 
initiator molecule starting the sensitization process and that a longer time is necessary to 
develop sensitization to Phl p 5 than to Phl p 1. In a German population of 101 grass pollen 
allergic adults (3) a higher frequency of IgE sensitization to both Plh p 1 and Phl p 4 (92%) was 
observed, however in our population the frequency of IgE sensitization to Phl p 4 was lower 
(42.2%); the discrepancy with our study is likely due to the use of a native form of Phl p 4, which 
carries highly cross-reacting CCD B-cell epitopes. Altogether, these results further confirm that 
the IgE sensitization to Phl p 1 is sufficient in most cases to corroborate a diagnosis of grass 
pollen allergy (12, 30, 31). This conclusion may be of great relevance in diagnostic algorithms for 
grass pollen AIT.  
 Phl p 7 – IgE sensitization to Phl p 7 (polcalcin) was relatively infrequent but strongly associated 
with asthma. During the IgE molecular spreading process, Phl p 7 is often the “last” molecule 
inducing an IgE response (15). Accordingly, our 38 Phl p 7 sensitized children were highly 
polymolecularly sensitized and had high levels of serum tIgE and grass-pollen sIgE. Therefore, 
the “asthma-biomarker” role of IgE to Phl p 7 is likely explained by a spurious association (Phl p 7 
sensitization being a proxy of extreme polysensitization) rather than by a direct causal-effect 
link. Nevertheless, the data suggest that testing IgE for Phl p 7 may be useful not only to explain 
cross- reactivity (32, 33), but  also as a quite specific biomarker of asthma among SARg patients.  
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 Phl p 12 – IgE sensitization to Phl p 12 (profilin) was observed in over 25% of the examined 
patients and it was strongly associated with Oral Allergy Syndrome. Our study therefore 
confirms that profilin is a known trigger of allergic reactions to plant-derived foods, mostly 
limited to the oral cavity (13, 34).  
Impact on grass pollen immunotherapy prescription  
Has the great heterogeneity of the IgE molecular sensitization profiles to grass pollen an influence on 
the efficacy and safety of grass pollen AIT? This question cannot be answered by our study. 
Interventional and prospective studies in patient cohorts are urgently needed to test the hypothesis 
(16,22), that the diagnostic biomarkers examined in our study may improve the efficacy of AIT and 
predict its safety (14). Nevertheless, our results also confirm that patients with AR symptoms during 
the grass pollen-season and a positive SPT/IgE assay to grass pollen extracts should be further 
examined to detect serum IgE antibodies to Phl p 1 and, if possible, to Phl p 2, Phl p 5, Phl p 7, Phl p 
11, and Phl p 12 (10). The identification of sensitization to Phl p 1 should followed by the 
prescription of grass pollen AIT. Our results also suggest that the detection of IgE to Phl p 12 
(profilin) should prompt further investigation of OAS. The presence of IgE to Phl p 7 will alert the 
doctor of a worse prognosis, a higher risk of asthma and a greater severity of SAR. Interestingly, 
Immunoblot inhibition experiments demonstrated that commercial pollen extracts for AIT, with the 
exception of Parietaria, are normally rich in profilin, while only grass pollen extracts seem to contain 
also in polcalcin (35). If this observation were confirmed, then grass pollen immunotherapy would be 
appropriated to induce a protective immune response to these two panallergens in polysensitized 
patients.  
Clinical relevance of IgE sensitization profiles - Our study population was big enough to test the 
hypothesis that molecular IgE sensitization profiles are of diagnostic value. The outcome of this 
analysis was rather frustrating, as no profile was associated with peculiar characteristic or with the 
severity of allergic disease. At least two facts may have contributed to this negative outcome. On 
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one hand, our study population is characterized by a very high prevalence of polysensitization to 
other pollens (birch, cypress, pellitory, olive tree, mugwort, plane tree) [Table e1], whose peak 
season widely overlaps with that of grass pollen. So allergic symptoms triggered by other pollens 
confounded the clinical relevance of grass pollen sensitization. Differently, in Northern Europe, the 
peak pollen season of grasses is shorter and unaccompanied by other pollens and the prevalence of 
polysensitization is lower (36, 37). Thus we speculate that the clinical relevance of testing IgE 
sensitization profiles in grass pollen allergic children may be stronger in such regions. On the other 
hand, the parameters used in our cross-sectional study to graduate the severity of SAR (i.e. ARIA 
classification based on a few simple quest ions)(20) did not allow a fine discrimination of symptoms 
severity (38). Therefore the clinical relevance of IgE sensitization profiles will have to be tested again 
in longitudinal studies, using a prospective registration of symptoms severity through symptoms-
medication scores along a full pollen season.(39) Similarly, our study design did not address the 
question whether different IgE sensitization profiles predict efficacy (22) and adverse reactions (14, 
40) to grass pollen immunotherapy.  
Limitations – We have to acknowledge additional study limitations. First, we tested sensitization to 
one grass pollen species only and the generalizability of our conclusions in settings and countries 
(e.g. Australia (2)) where Phleum pratense is less representative of the dominating grass pollen 
species may be questioned. Second, the relative frequency of IgE sensitization to Phleum pratense 
and other grass pollens in patients with seasonal allergic rhinitis is higher in Northern than in 
Southern Italy (17). Phleum pratense is the most relevant grass pollen allergen in Italy, however 
other grasses (e.g. Bermuda grass, Lolium perenne) may play in patients a role in triggering seasonal 
allergic symptoms (32). Third, the data on the SAR characteristics were based only on a retrospective 
questionnaire and, therefore, exposed to potential recall bias. Fourth, asthma and OAS could not be 
confirmed by lung tests and food challenge, respectively, and over-reporting cannot be excluded. 
Fifth, we examined a pediatric population, therefore specific studies among adults should be 
performed to test whether the same conclusions could be applied to older groups. 
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However, a recent Italian study performed in 11,235 adult patients with AR showed percentages of 
IgE sensitization to Phleum pratense molecules comparable with our data (41).  
Conclusions - In conclusion, this nationwide study identifies three biomarkers in children population, 
Phl p 1, Phl p 7 and Phl p 12 that can be useful in the diagnostic work-up of the child with grass 
pollen allergy. The study also shows an extreme heterogeneity of combinatorial molecular IgE 
sensitization profiles, whose clinical usefulness is limited to a Mediterranean country. Prospective 
studies in patient cohorts are now needed to expand our knowledge on the stability and predictive 
value of the observed associations. 
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Legend to figures 
 
Figure 1 – a) Molecular profiles of IgE sensitization (≥ 0.35 KUA/l) to Phleum pratense molecules: rPhl 
p 1, rPhl p 2,  rPhl p 4, rPhl p 5, rPhl p 6, rPhl p 7, rPhl p 11, rPhl p 12 in 1120 children with skin 
reaction to Phleum pratense (wheal ≥ 3 mm) and tested for sIgE to all considered molecules. The 
Allergen Profile Codification System (APCS) code, the number of children belonging to that specific 
code (n), the relative frequency (%) and the cumulative frequency (%) are shown. The profiles are 
ordered by decreasing frequency. b) Prevalence of IgE response to Phleum pratense allergens, 
according to the molecular categories. “Monomolecular”: IgE sensitization to 1 molecule only; 
“oligomolecular”: 2-4 molecules; “polymolecular”: 5-8 molecules. 
Figure 2 – Levels of specific IgE (sIgE) to Phleum pratense and Phl p 1, sum of sIgE to pollens, and 
number of pollens recognized by SPT, according to the number of Phleum pratense molecules 
recognized by IgE. Lines show the geometric mean level of positive sIgE response (≥0.35 kU/L) and 
the number of pollens recognized by SPT. *p for trend <0.001.  § Sensitization to pollens: skin 
reactions to pollens (wheal ≥3 mm). SPT extracts included: Betula verrucosa, Cupressus arizonica, 
Platanus orientalis, Olea europaea, Parietaria judaica, Artemisia vulgaris, Plantago lanceolata. 
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p-value*
Number
Age (ys) (mean,SD) 10.5 3.4 9.7 3.2 0.004
Males (n, %) 772 69 82 61 0.052
Familiar atopy ^
Mother (n, %) 492 44 62 46 0.659
Father (n, %) 441 39 48 36 0.390
Geographic Area (n, %)
North 370 33 20 15
Center 532 48 57 42
South & Islands 218 19 58 43
Characteristics of SAR
Age at onset of SAR (ys) (mean, SD) 5.3 2.9 4.9 2.5 0.175
Duration of SAR (ys) (mean, SD) 5.2 3.3 4.7 3.1 0.157
Moderate - severe SAR (n, %) 583 51 59 44 0.067
Months with symptoms (n) (mean, SD) 4.2 1.8 4.4 1.8 0.329
Pollen season months with symptoms 
(n) (mean, SD)
3.9 1.4 3.8 1.4 0.875
Asthma (n, %) 415 37 62 46 0.045
Oral allergy syndrome (n, %) 265 24 31 23 0.857
Atopic reactivity
Overall SPT reactivity
 to pollens (mm) (mean,SD) §
36.5 21 15.5 9 <0.001
Levels of total IgE (kU/L) (mean,SD)° 2.6 0.5 2.5 0.5 0.002
† Skin sensiti zation to P pratense (wheal ≥ 3 mm)
# Subjects not sensitized to P pratense (SPT wheal <3 mm)
^ At least one among hay fever, asthma or atopic dermatitis
°Log ₁₀ trasformed data of T-IgE were used.
* Chi squared test was used to compare frequencies; T-test for normally distributed indipendent 
samples and Mann-Whitney U-Test for not normally distributed indipendent samples. 
§  SPT extracts included: Betula verrucosa, Cupressus arizonica, Platanus orientalis, Olea europaea, 
Parietaria judaica, Artemisia vulgaris, Plantago lanceolata
Table 1. Characteristics of 1255 Italian children with seasonal allergic 
rhinoconjunctivitis (SAR) included or excluded from the study.
Study 
population†
Excluded #
1120 135
<0.001
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Figure 2 
 
 
 
 
 
 
  
